OlaReDo - Olaratumab and Rechallenge With Doxorubicin in Soft Tissue Sarcoma Patients
Status:
Terminated
Trial end date:
2020-06-25
Target enrollment:
Participant gender:
Summary
This is an exploratory, prospective, open label, single arm, phase II-study for the
evaluation of efficacy and feasibility (as determined by safety and tolerability) of
olaratumab and doxorubicin rechallenge in anthracycline pretreated locally advanced
(unresectable) or metastatic soft tissue sarcoma patients.
Phase:
Phase 2
Details
Lead Sponsor:
IKF Klinische Krebsforschung GmbH at Krankenhaus Nordwest Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest